



# Anxiety and depression in keratotic oral lichen planus: a multicentric study from the SIPMO

Daniela Adamo<sup>1</sup> · Elena Calabria<sup>1</sup> · Federica Canfora<sup>1</sup> · Noemi Coppola<sup>1</sup> · Stefania Leuci<sup>1</sup> · Martina Mignogna<sup>1</sup> · Lorenzo Lo Muzio<sup>2</sup> · Francesca Spirito<sup>2</sup> · Michele Giuliani<sup>2</sup> · Lorenzo Azzi<sup>3</sup> · Marta Dani<sup>3</sup> · Giuseppe Colella<sup>4</sup> · Chiara Colella<sup>4</sup> · Lucio Montebugnoli<sup>5</sup> · Davide Bartolomeo Gissi<sup>5</sup> · Mario Gabriele<sup>6</sup> · Marco Nisi<sup>6</sup> · Andrea Sardella<sup>7</sup> · Giovanni Lodi<sup>7</sup> · Elena Maria Varoni<sup>7</sup> · Amerigo Giudice<sup>8</sup> · Alessandro Antonelli<sup>8</sup> · Alessio Gambino<sup>9</sup> · Giuliana Antonucci<sup>9</sup> · Paolo Vescovi<sup>10</sup> · Marco Meleti<sup>10</sup> · Alessandra Majorana<sup>11</sup> · Elena Bardellini<sup>11</sup> · Giuseppina Campisi<sup>12</sup> · Vera Panzarella<sup>12</sup> · Francesco Spadari<sup>13</sup> · Umberto Garagiola<sup>13</sup> · Monica Pentenero<sup>14</sup> · Samuele Sutura<sup>14</sup> · Matteo Biasotto<sup>15</sup> · Giulia Ottaviani<sup>15</sup> · Margherita Gobbo<sup>15,16</sup> · Luca Guarda Nardini<sup>16</sup> · Umberto Romeo<sup>17</sup> · Gianluca Tenore<sup>17</sup> · Rosario Serpico<sup>4</sup> · Alberta Lucchese<sup>4</sup> · Carlo Lajolo<sup>18</sup> · Gioele Gioco<sup>18</sup> · Massimo Aria<sup>19</sup> · Luca D'Aniello<sup>20</sup> · Michele Davide Mignogna<sup>1</sup> · SIPMO (Italian Society of Oral Pathology, Medicine)

Received: 7 August 2022 / Accepted: 3 February 2023  
© The Author(s) 2023

## Abstract

**Objectives** Oral lichen planus with exclusive keratotic reticular, papular, and/or plaque-like lesions (K-OLP) is a clinical pattern of OLP that may be associated with a complex symptomatology and psychological alteration. The aim of the study was to evaluate the prevalence of anxiety (A) and depression (D) in patients with K-OLP, analyzing the potential predictors which can affect mental health status.

**Methods** Three hundred K-OLP patients versus 300 healthy controls (HC) were recruited in 15 Italian universities. The Numeric Rating Scale (NRS), Total Pain Rating Index (T-PRI), and Hamilton Rating Scales for Depression and for Anxiety (HAM-D and HAM-A) were administered.

**Results** The K-OLP patients showed statistically higher scores in the NRS, T-PRI, HAM-D, and HAM-A compared with the HC ( $p$ -value  $< 0.001^{**}$ ). A and D were found in 158 (52.7%) and 148 (49.3%) K-OLP patients. Strong linear correlations were identified between HAM-A, HAM-D, NRS, T-PRI, and employment status and between HAM-D, HAM-A, NRS, T-PRI, employment status, and female gender. Multivariate logistic regression revealed that HAM-D and HAM-A showed the greatest increase in the R2 value for A and D in the K-OLP patients, respectively (DR2 = 55.5%  $p$ -value  $< 0.001^{**}$ ; DR2 = 56.5%  $p$ -value  $< 0.001^{**}$ ).

**Conclusions** The prevalence of A and D is higher in the K-OLP patients compared with the HC, also found in K-OLP subjects without pain, suggesting that the processing of pain may be in a certain way independent of the processing of mood.

**Clinical relevance** Mood disorders and pain assessment should be carefully performed in relation to K-OLP to obtain a complete analysis of the patients.

**Keywords** Keratotic oral lichen planus · Depression · Anxiety · Mood disorder · Pain

---

Daniela Adamo and Elena Calabria have equally contributed to the study and must be considered as first authors.

---

✉ Federica Canfora  
federica.canfora@live.it

Extended author information available on the last page of the article

## Introduction

Oral lichen planus (OLP) is a chronic immune-mediated, inflammatory disease of the oral mucosa, affecting 1.01% of the population with a higher prevalence in Europe (1.38%) [1, 2]. The pathogenic mechanism of the illness remains unknown but genetic, environmental, and local factors and psychological distress may have a role in the activation of

the host immunological system against the oral mucosa, supporting the hypothesis of an immune-mediated disease [3, 4].

OLP may present with different clinical patterns, ranging from keratotic manifestations (white reticular, papular, and/or plaque-like lesions), usually symmetrical and bilateral, to predominantly non-keratotic OLP (atrophic, erythematous, erosive, ulcerative and/or bullous lesions) [2, 4]. Moreover, OLP is included among the group of potentially malignant disorders of the oral mucosa, with a risk of progression to cancer of 2.28% [5].

Despite the OLP with exclusive keratotic manifestations (K-OLP) being usually considered asymptomatic compared with non-keratotic OLP, recent studies have suggested a high prevalence of oral discomforts, a burning sensation and pain with additional oral symptoms such as taste disturbance, xerostomia, and globus pharyngeus (a non-painful sensation of a lump or foreign body in the throat). Such symptoms are not related to clinical features because they have been revealed also in oral sites without lesions [6–8].

The oral symptomatology associated with the fear of cancer development may contribute to emotional and mood changes [9, 10], as suggested by the higher levels of anxiety (A) and depression (D) reported in these patients compared with healthy subjects. In addition, several studies have highlighted that A and D may be considered as triggers both in relation to the onset but also to the exacerbation of the disease, which in turn may amplify the subjective oral symptoms [11–13]. The synergic association between OLP, A, and D may further contribute to a poor quality of life and an increased level of stress among such subjects. [14]

Despite recent studies have suggested a strong association between OLP and mood disorders [7, 15, 16], with an overall estimated prevalence of 54.76% and 31.19% of OLP patients suffering from A and D [1], few studies have analyzed the prevalence of A and D in a subset of patients with K-OLP. Therefore, we decided to perform a multicentric study in our country in a large cohort of patients with K-OLP to confirm this association and to better understand the role of the sociodemographic profile, risk factors, and oral symptoms in the development of A and D in this subgroup of OLP patients. Thus, the aim of this study was to evaluate the prevalence of A, D, pain, and additional intra-oral symptoms in a wide cohort of Italian patients with K-OLP, compared with a group of healthy controls (HC), analyzing the predictors that can cause this psychological impairment.

## Materials and methods

This study is a descriptive secondary analysis of a multicentric clinical observational study which was conducted between January 2019 and February 2020, involving fifteen

Italian University departments of Oral Medicine belonging to the Italian Society of Oral Pathology and Medicine (Società Italiana di Patologia e Medicina Orale) (SIPMO) [6].

The study was previously approved by the Ethics Committee of Federico II University of Naples, (Approval Number:184/18) and conducted in accordance with the ethical principles of the World Medical Association Declaration of Helsinki. The adopted methods conformed with the Strengthening of the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for observational studies [17].

## Participants and procedure

As described in our previous research, [6] all potentially eligible participants were invited to participate in the study and provided their written informed consent. The inclusion and exclusion criteria were established in accordance with the previous SIPMO studies, in order to follow the same guidelines.

Additionally, the procedures used to enlist the patients in the group and the screening process conformed with those adopted in the other studies, involving expert clinicians in oral medicine and psychiatry for the psychological assessment. Sociodemographic characteristics were formerly recorded, such as the anamnestic evaluation [6]. The acronym K-OLP (keratotic oral lichen planus) refers to the OLP characterized by the presence of exclusive keratotic manifestations, namely papular, reticular, and/or plaque-like white lesions with histopathology showing the presence of keratosis. As previously described, in all cases the OLP diagnosis was based on clinical and histopathological findings [6].

Questionnaires were administered to the K-OLP patients and HC in order to completely analyze the intensity of pain, through the Numerical Rating Scale (NRS) [18, 19]; the quality of pain experienced, through the Total Pain Rating Index (T-PRI) [20]; D, using the Hamilton Rating Scale for Depression (HAM-D) [21, 22], and A, with the Hamilton Rating Scale for Anxiety (HAM-A) [23]. These questionnaires have been described in detail in our previous studies [6, 7].

## Statistical analysis

The statistical analysis was performed using the SPSS software v. 23. Descriptive statistics, including means, standard deviations, medians, and interquartile range (IQR), were used to analyze the socio-demographic and clinical characteristics of the groups. The Pearson chi-square test and Fisher's exact test were used to assess the significant differences between the percentages, and the differences associated with *p*-values less than 0.05 or 0.01 were considered moderately or strongly significant, respectively. The non-parametric

Mann-Whitney U test was employed to evaluate differences between the median scores of the HAM-A, HAM-D, NRS, and T-PRI in the groups. P-values < 0.05 were considered to reflect a statistical significance. The Spearman test was used to analyze the correlation between the qualitative and quantitative predictors and HAM-A and HAM-D median scores.

To identify potential predictors of A and D in K-OLP, multiple linear regression analyses were performed, considering sociodemographic parameters (age, gender, education, marital status, employment status) and intensity and quality of pain (NRS and T-PRI). Full models, when all the parameters were entered simultaneously, were used to evaluate the relative contributions of these variables to pain.

In detail, a sequential regression model analysis including predictors, one by one, to obtain unadjusted coefficient estimations was performed. Moreover, in a final step, we performed a full model analysis considering all predictors, simultaneously, to estimate adjusted coefficients. In all steps, we provided standard errors of model coefficients which measure the statistical precision of inference estimation of the model parameters.

### Sample size calculation

The sample size, namely 300 subjects, was set by fixing a test power of no less than 90% associated with a significance of no more than 5% (software G\*Power 3.1.9.7 by Dusseldorf University). This sample size calculation was performed using the effect size estimation from a previously published research study regarding scales of mood disorders and pain [7, 24].

### Results

A total of 600 participants were enrolled, 300 K-OLP patients and 300 HC. The sociodemographic characteristics of both groups are shown in Table 1. In the sample of K-OLP and HC, the prevalence of women and men was 58.3% (175) and 41.7% (125), respectively, with no difference in the mean age between the two groups ( $p$ -value: 0.597). Statistically significant differences were found in relation to employment and marital status. A lower proportion of K-OLP patients were employed (108; 36%) compared to the HC (155; 51.7%) ( $p$ -value: 0.001\*\*). In contrast, a statistically significant higher percentage of K-OLP patients were married (217; 72.3%) in comparison to the HC (176; 58.7%) ( $p$ -value: < 0.001\*\*). In addition, the HC presented a higher education ( $p$ -value: < 0.001\*\*) and were characterized by a significantly higher percentage of smokers (32.0%) ( $p$ -value: 0.001\*\*). No differences were detected in terms of BMI and

**Table 1** Socio-demographic profile, body mass index, disease onset, and risk factors in the 300 K-OLP patients and 300 HC

Demographic variables	K-OLP patients N° (%)	HC N° (%)	$p$ -value
Gender			
Male	125 (41.7)	125 (41.7)	1.000
Female	175 (58.3)	175 (58.3)	
Employment			
Employed	108 (36.0)	155 (51.7)	< 0.001**
Not employed	192 (64.0)	145 (48.3)	
Family situation			
Married	217 (72.3)	176 (58.7)	< 0.001**
Not married	83 (27.7)	124 (41.3)	
	Mean $\pm$ SD	Mean $\pm$ SD	$p$ -value
Age (in years)	65.2 $\pm$ 12.2	64.2 $\pm$ 16.9	0.597
Education (in years)	10.9 $\pm$ 4.05	13.6 $\pm$ 4.5	< 0.001**
Body mass index	24.9 $\pm$ 3.92	24.3 $\pm$ 3.63	0.065
Disease onset (years)	4.5 $\pm$ 2.3	/	/
Risk factors	N° (%)	N° (%)	$p$ -value
Smoker			
Yes	66 (22.0)	96 (32.0)	0.001**
No	234 (78.0)	204 (68.0)	
Alcohol use			
Yes ( $\leq$ 14 units/week)	91 (30.3)	95 (31.7)	0.767
No	209 (69.7)	205 (68.3)	

The significant difference between the percentages was measured by the Pearson chi-square test. \* Significant  $0.01 < p \leq 0.05$ , \*\* Significant  $p \leq 0.01$

Abbreviation: *K-OLP*, keratotic oral lichen planus; *HC*, healthy controls

alcohol consumption between the groups ( $p$ -values: 0.065, 0.767).

Table 2 shows the distributions of systemic comorbidities and drug consumption among the groups. Specifically, a higher percentage of the K-OLP patients suffered from gastro-esophageal reflux (46; 15.3%) and from benign prostatic hypertrophy (21; 7.0%) compared to the HC (27; 9.0% and 8; 2.7% respectively) ( $p$ -values: 0.024\* and 0.021\*). Further, a moderately significant difference was observed with respect to the intake of levothyroxine sodium, which was more prevalent among the K-OLP group (36, 12%;  $p$ -value: 0.023\*). No further differences were recorded for all the other comorbidities and drugs.

Table 3 shows the frequencies of the oral symptoms for the K-OLP and the HC groups. The most frequently reported oral symptom among the K-OLP group was a painful sensation (149; 58.3%), described as burning in character, which was localized in one or more sites in 43.0% (103) of the patients while in 15.3% (46) it was diffuse throughout the oral mucosa even where there were no lesions [6]. A statistically strongly significant higher percentage of the

**Table 2** Frequency of systemic diseases and drug consumption in the 300 K-OLP patients and 300 HC

	K-OLP N° (%)	HC N° (%)	P-value
<b>Systemic diseases</b>			
Essential hypertension	98 (32.7)	78 (26.0)	0.088
Hypercholesterolemia	67 (22.3)	50 (16.7)	0.099
Gastro-esophageal reflux disease	46 (15.3)	27 (9.0)	0.024*
Hypothyroidism	34 (11.3)	21 (7.0)	0.089
Diabetes	26 (8.3)	21 (7.0)	0.598
Previous malignant disease	24 (8.0)	16 (5.3)	0.252
Benign prostatic hypertrophy	21 (7.0)	8 (2.75)	0.021*
Endocrine disease	11 (3.7)	6 (2.0)	0.325
Hepatitis C	10 (3.3)	4 (1.3)	0.174
Asthma	7 (2.3)	7 (2.3)	1.000
Previous myocardial infarction	6 (2.0)	8 (2.7)	0.788
Hyperthyroidism	5 (1.7)	4 (1.3)	1.000
Hepatitis B	4 (1.3)	0 (0.0)	0.124
<b>Drug consumption</b>			
Beta-adrenergic receptor blockers	47 (15.7)	35 (11.7)	0.191
Simvastatin	43 (14.3)	41 (13.7)	0.906
Proton pump inhibitors	42 (14.0)	35 (11.7)	0.464
Levothyroxine sodium	36 (12)	19 (6.3)	0.023*
Antiplatelets	35 (11.7)	24 (8.0)	0.17
ACE-inhibitors	28 (9.3)	31 (10.3)	0.784
Angiotensin II receptor blockers	24 (8.0)	17 (5.7)	0.332
Diuretics	24 (8.0)	24 (8.0)	1.000
Metformin	24 (8.0)	16 (5.3)	0.252
Blood thinner	15 (5.0)	6 (2.0)	0.073
Insulin	8 (2.7)	6 (2.0)	0.788

The significant difference between percentages was measured by Fisher's exact test. \* Significant  $0.01 < p \leq 0.05$ , \*\* Significant  $p \leq 0.01$

Abbreviation: K-OLP, keratotic oral lichen planus; HC, healthy controls

K-OLP patients suffered from pain/burning, xerostomia, dysgeusia, subjective halitosis, globus pharyngeus, itching, intraoral foreign body sensation, tingling sensation ( $p$ -value:  $< 0.001^{**}$ ) and dysosmia ( $p$ -value:  $0.002^{**}$ ) in comparison with the HC. A moderately significant difference was found with respect to sialorrhea ( $p$ -value:  $0.032^{*}$ ), and occlusal dysesthesia ( $p$ -value:  $0.03^{*}$ ) while no difference was revealed with regard to oral dyskinesia ( $p$ -value:  $0.068$ ) and a change in the tongue morphology ( $p$ -value:  $1.000$ ).

Table 4 shows the median and interquartile range of the clinical parameters (NRS, T-PRI, HAD-A, and HAD-D) and a comparison of the frequencies of the patients and controls in relation to the severity of the pain and the psychological parameters.

Overall, the K-OLP patients presented statistically significantly higher median total scores for the NRS, T-PRI,

HAM-A, and HAM-D in comparison to the HC ( $p$ -values:  $< 0.001^{**}$ ). Additionally, there was a significantly different frequency distribution between the K-OLP patients and the HC with respect to the NRS categories ( $p$ -values:  $< 0.001^{**}$ ), as only 39.7% (119) of the K-OLP group presented no pain compared to 80.7% (242) of the HC. In detail, 30.3% (91), 17% (51), and 13% (39) of the K-OLP patients presented mild, moderate, and severe pain, respectively, compared to 12% (36), 4.7% (14), and 2.7% (8) of the HC. Statistically significant differences in the frequency distributions were also detected when analyzing the severity scores of the HAM-A and HAM-D ( $p$ -values:  $< 0.001^{**}$  and  $0.003^{**}$  respectively). Indeed, no A was reported in 47.3% (142) of the K-OLP patients compared to 62% (186) of the HC. A was found in 52.7% (158) of the K-OLP group; 40.7% (122) presented mild A, 7.7% (23) moderate A, and 4.3% (13) severe A in comparison with 32% (96), 5% (15) and 1% (3) of the HC, respectively. With regard to the HAM-D score categories, instead, 50.7% (152) of the K-OLP patients reported no D compared with 64% (192) of the HC. D was found in 49.3% (148) of the K-OLP group; 39.3% (118) presented mild D, 7.7% (23) moderate D, and 2.3% (7) severe D, compared with 31% (94), 3% (9), and 1.7% (5) of the HC.

Table 5 shows the frequency distributions of A and D (the HAM-A and HAM-D scores) in relation to the intensity of pain (the NRS scores). Interestingly, A and D were reported in 43.7% (52) and in 47% (56) of the patients with K-OLP without pain. In particular, we have also found that the 62.3% (109) of K-OLP females suffered from A versus the 38.4% (48) of K-OLP males and that the 57.1% (100) of K-OLP females suffered from depression versus the 37.6% (47) of K-OLP males (data not displayed in the table).

Tables 6 and 7 show the dependence analyses between the HAM-A and HAM-D scores and the quantitative and qualitative variables. There was a positive correlation between the HAM-A scores and the HAM-D, NRS, and T-PRI scores ( $p$ -values:  $< 0.001^{**}$ ), while no correlation was found with age, education, and BMI ( $p$ -values:  $0.132$ ,  $0.051$ ,  $0.553$  respectively). Similarly, a positive correlation was also found between the HAM-D scores and the HAM-A, NRS, and T-PRI scores ( $p$ -values:  $< 0.001^{**}$ ). Furthermore, both the HAM-A and HAM-D scores were positively correlated with the female gender and with unemployment status (HAM-A  $p$ -values:  $0.001^{**}$ ,  $0.022^{*}$ ; HAM-D  $p$ -values:  $0.010^{**}$ ,  $0.020^{*}$ ).

The results of the simultaneous multiple linear regression analyses for the K-OLP group, predicting A and D (HAM-A and HAM-D) are shown in Table 8. The first model tests the contribution of the demographic variables to A (HAM-A) revealing that only the female gender was found to be statistically moderately significant ( $p$ -value  $0.046^{*}$ ). Instead, the addition of D (model 2) resulted in a significant increase in the R2 value for

**Table 3** Frequency of oral symptoms in the 300 K-OLP patients and 300 HC

Oral symptoms	K-OLP N° (%)	HC N° (%)	P-value
Pain/burning localized in one or more sites	103 (43.0)	15 (5.4)	<0.001**
Pain/burning diffuse	46 (15.3)	7 (2.3)	<0.001**
Xerostomia	101 (33.7)	33 (11)	<0.001**
Dysgeusia	58 (19.3)	13 (4.3)	<0.001**
Subjective halitosis	55 (18.3)	27 (9)	0.001**
Globus pharyngeus	40 (13.3)	11 (3.7)	<0.001**
Intraoral foreign body sensation	35 (11.7)	10 (3.3)	<0.001**
Itching	34 (11.4)	9 (3)	<0.001**
Sialorrhea	31 (10.3)	16 (5.3)	0.032*
Tingling sensation	29 (9.7)	6 (2)	<0.001**
Occlusal dysesthesia	23 (7.7)	10 (3.3)	0.03*
Dysosmia	19 (6.3)	4 (1.3)	0.002**
Oral dyskinesia	7 (2.3)	1 (0.3)	0.068
Change in tongue morphology	2 (0.7)	1 (0.3)	1.000

The significant difference between the percentages was measured by Fisher's exact test. \* Significant 0.01 < p ≤ 0.05, \*\* Significant p ≤ 0.01

Abbreviation: *K-OLP*, keratotic oral lichen planus; *HC*, healthy controls

**Table 4** Score analysis of the pain, anxiety, and depression of the 300 K-OLP patients and 300 HC

	K-OLP	HC	P-value
Clinical parameters	Median; IQR	Median; IQR	
NRS	2 [0–5]	0 [0–0]	<0.001**
T-PRI	2 [0–5]	0 [0–0]	<0.001**
HAM-A	7 [3–12]	5 [1–10]	<0.001**
HAM-D	6 [3–12]	5 [2–9]	<0.001**
Score analysis of pain intensity	N° (%)	N° (%)	p-value
NRS			
Absent (0)	119 (39.7)	242 (80.7)	<0.001**
Mild pain (1–4)	91 (30.3)	36 (12)	
Moderate pain (5–6)	51 (17)	14 (4.7)	
Severe pain (7–10)	39 (13)	8 (2.7)	
Score analysis of psychological parameters	N° (%)	N° (%)	p-value
HAM-A			
No anxiety (<7)	142 (47.3)	186 (62)	<0.001**
Mild (7–17)	122 (40.7)	96 (32)	
Moderate (18–24)	23 (7.7)	15 (5)	
Severe (> 24)	13 (4.3)	3 (1)	
HAM-D			
No depression (<7)	152 (50.7)	192 (64)	0.003**
Mild (7–17)	118 (39.3)	94 (31)	
Moderate (18–24)	23 (7.7)	9 (3)	
Severe (> 24)	7 (2.3)	5 (1.7)	

IQR is the interquartile range. The significant difference between medians was measured by the Mann-Whitney *U* test

\* Significant 0.01 < p ≤ 0.05, \*\* Significant p ≤ 0.01

The significant difference between the HAM-A and HAM-D percentages affected by HAM-A and HAM-D was measured by Fisher's exact test. \* Significant 0.01 < p ≤ 0.05, \*\* Significant p ≤ 0.01

Abbreviations: *K-OLP*, keratotic oral lichen planus; *HAM-A*, Hamilton Rating Scale for Anxiety; *HAM-D*, Hamilton Rating Scale for Depression; *HC*, healthy controls; *NRS*, Numeric Rating Scale; *T-PRI*, Total Pain Rating Index

**Table 5** Frequency distribution of anxiety and depression scores (HAM-A, HAM-D) depending on the severity of the pain (NRS)

Score analysis of psychological parameters versus pain intensity	K-OLP N° (%)				P-value	HC N° (%)				P-value
	NRS					NRS				
	Absent	Mild pain	Moderate pain	Severe pain		Absent	Mild pain	Moderate pain	Severe pain	
<b>HAM-A</b>										
No anxiety (<7)	67 (56.3)	45 (49.5)	21 (41.2)	9 (23.1)	0.003**	158 (65.3)	22 (61.1)	3 (21.4)	3 (37.5)	0.001**
Mild (7–17)	46 (38.7)	37 (40.7)	19 (37.3)	20 (51.3)		75 (31)	10 (27.8)	8 (57.1)	3 (37.5)	
Moderate (18–24)	3 (2.5)	5 (5.5)	8 (15.7)	7 (17.9)		7 (2.9)	4 (11.1)	2 (14.3)	2 (25)	
Severe (> 24)	3 (2.5)	4 (4.4)	3 (5.9)	3 (7.7)		2 (0.8)	0 (0)	1 (7.1)	0 (0)	
<b>HAM-D</b>										
No depression (<7)	63 (52.9)	52 (57.1)	22 (43.1)	15 (38.5)	0.093	160 (66.1)	23 (63.9)	5 (35.7)	4 (50)	0.012*
Mild (7–17)	47 (39.5)	34 (37.4)	21 (41.2)	16 (41)		74 (30.6)	9 (25)	8 (57.1)	3 (37.5)	
Moderate (18–24)	8 (6.7)	3 (3.3)	7 (13.7)	5 (12.8)		7 (2.9)	2 (5.6)	0 (0)	0 (0)	
Severe (> 24)	1 (0.8)	2 (2.2)	1 (2)	3 (7.7)		1 (0.4)	2 (5.6)	1 (7.1)	1 (12.5)	

The significance difference between the NRS percentages affected by HAM-A and HAM-D among the K-OLP patients and controls was measured by the Fisher's exact test. \* Significant  $0.01 < p \leq 0.05$ , \*\* Significant  $p \leq 0.01$

Abbreviations: K-OLP, keratotic oral lichen planus; HAM-A, Hamilton Rating Scale for Anxiety; HAM-D, Hamilton Rating Scale for Depression; HC, healthy controls; NRS, Numeric Rating Scale



**Table 6** Dependence analysis between HAM-A and quantitative and qualitative predictors in the K-OLP patients

HAM-A		
Quantitative predictors	<i>p</i> -value	
Age	0.087 (0.132)	
Education	− 0.116 (0.051)	
BMI	0.034 (0.553)	
HAM-D	0.742 (< 0.001**)	
NRS	0.231 (< 0.001**)	
T-PRI	0.333 (< 0.001**)	
Qualitative predictors	<i>Median [Q1:Q3]</i>	<i>p</i> -value
Gender		
Female	8 [4–13]	0.001**
Male	5 [1.5–11]	
Marital status		
Married	7 [3–11.2]	0.537
Not married	7.5 [3–12.5]	
Employment status		
Employed	6 [1–12]	0.022*
Not employed	8 [4–12]	
Smoking status		
Smoker	9 [4–15]	0.059
Non-smoker	7 [3–11]	
Alcohol use		
Yes	6 [2–12]	0.126
No	8 [4–11.8]	

*r* is Spearman's correlation coefficient. *p*-value—\*Significant 0.01 < *p*-value ≤ 0.05. \*\*Significant *p*-value ≤ 0.01

The significant difference between the medians was measured by the Mann–Whitney *U* test

Abbreviations: *BMI*, body mass index; *K-OLP*, keratotic oral lichen planus; *HAM-A*, Hamilton Rating Scale for Anxiety; *HAM-D*, Hamilton Rating Scale for Depression; *HC*, healthy controls; *NRS*, Numeric Rating Scale; *T-PRI*, Total Pain Rating Index

HAM-A (DR2 = 55.5%; *p*-value < 0.001\*\*), similar to the addition of pain intensity (NRS) (model 3) (DR2 = 6.2%; *p*-value < 0.001\*\*) and the addition of pain quality (T-PRI) (model 4) (DR2 = 20%; *p*-value < 0.001\*\*). The final full model (model 5) in which all of the variables were entered simultaneously could explain 59.8% of the variance in the total scores of the HAM-A for the K-OLP patients (*p*-value: 0.001\*\*). With respect to D (HAM-D), no demographic variables (model 1) were found to be statistically significant in the increase in the R2 value, while the addition of A (HAM-A) contributed to a significant increase in the R2 value (DR2 = 56.2%, *p*-value: < 0.001\*\*). The addition of pain intensity (NRS) and pain quality (T-PRI) in models 3 and 4, respectively, resulted in an increase in the R2 value for the HAM-D scores (NRS DR2 = 3.6%, *p*-value: < 0.001\*\*; T-PRI DR2 = 16.9%, *p*-value: < 0.001\*\*). The final full model (model 5) could

**Table 7** Dependence analysis between HAM-D and quantitative and qualitative predictors in the K-OLP patients

HAM-D		
Quantitative predictors	<i>p</i> -value	
Age	0.096 (0.095)	
Education	− 0.089 (0.136)	
BMI	0.029 (0.613)	
HAM-A	0.742 (< 0.001**)	
NRS	0.153 (< 0.001**)	
T-PRI	0.273 (< 0.001**)	
Qualitative predictors	<i>Median [Q1:Q3]</i>	<i>p</i> -value
Gender		
Female	7 [3–13]	0.010**
Male	5 [2–9.5]	
Marital status		
Married	6 [3–11]	0.145
Not married	8.5 [2.75–14.2]	
Employment status		
Employed	5 [1.75–9.25]	0.020*
Not employed	7 [3–13]	
Smoking status		
Smoker	8.5 [3–13.2]	0.219
Non-smoker	6 [3–11]	
Alcohol use		
Yes	6 [2–10]	0.204
No	7 [3.25–12]	

*r* is Spearman's correlation coefficient. *p*-value—\*Significant 0.01 < *p*-value ≤ 0.05. \*\*Significant *p*-value ≤ 0.01

The significant difference between the medians was measured by the Mann–Whitney *U* test

Abbreviations: *BMI*, body mass index; *K-OLP*, keratotic oral lichen planus; *HAM-A*, Hamilton Rating Scale for Anxiety; *HAM-D*, Hamilton Rating Scale for Depression; *HC*, healthy controls; *NRS*, Numeric Rating Scale; *T-PRI*, Total Pain Rating Index

explain 58.7% of the variance of the HAM-D total scores for the K-OLP patients. (*p*-value: 0.001\*\*).

## Discussion

The bidirectional link between mood disorders and OLP is well recognized in the literature in that patients with A and D had an almost three or four times greater risk of developing OLP compared with subjects without any psychological impairment [24, 25]. On the other hand, OLP patients are more prone to develop psychiatric comorbidities [16, 26].

A and D are the most common medical comorbidities associated with OLP, as suggested by several studies [27, 28] and by a recent systematic review and meta-analysis [1], especially in patients with non-keratotic OLP, a condition

**Table 8** Multiple linear regression analysis predicting HAM-A and HAM-D in the 300 K-OLP patients

	Model 1		Model 2		Model 3		Model 4		Model 5	
	Beta (SE)	P-value	Beta (SE)	P-value	Beta (SE)	P-value	Beta (SE)	P-value	Beta (SE)	P-value
<b>HAM-A K-OLP</b>										
Age	-0.01 (0.05)	0.860	0.01 (0.03)	0.729	-0.01 (0.05)	0.869	-0.03 (0.04)	0.521	0.01 (0.03)	0.755
Gender (F)	1.99 (0.99)	0.046*	0.95 (0.66)	0.153	1.19 (0.98)	0.227	0.78 (0.89)	0.387	0.36 (0.64)	0.574
Years of education	-0.19 (0.13)	0.144	-0.13 (0.09)	0.134	-0.18 (0.13)	0.152	-0.15 (0.12)	0.184	-0.11 (0.08)	0.176
Marital status (married)	-1.28 (1.07)	0.233	-0.36 (0.71)	0.608	-1.13 (1.03)	0.275	-0.8 (0.95)	0.401	-0.33 (0.67)	0.625
Employment status (employed)	-0.04 (1.22)	0.973	0.66 (0.81)	0.415	-0.33 (1.18)	0.779	-0.92 (1.09)	0.402	0.54 (0.78)	0.487
HAM-D			0.82 (0.04)	<0.001**					0.65 (0.05)	<0.001**
NRS					0.69 (0.16)	<0.001**			-0.01 (0.14)	0.927
T-PRI							0.76 (0.09)	<0.001**	0.25 (0.09)	0.006**
R <sup>2</sup> (%)	1.6	0.093	57.1	<0.001**	7.8	<0.001**	21.6	<0.001**	61.4	<0.001**
R <sup>2</sup> change (%)			55.5	<0.001**	6.2	<0.001**	20	<0.001**	59.8	<0.001**
<b>HAM-D K-OLP</b>										
Age	-0.02 (0.05)	0.596	-0.02 (0.03)	0.542	-0.03 (0.04)	0.594	-0.04 (0.04)	0.324	-0.03 (0.03)	0.329
Gender (F)	1.28 (0.92)	0.162	-0.09 (0.61)	0.876	0.71 (0.92)	0.441	0.26 (0.85)	0.757	-0.44 (0.61)	0.469
Years of education	-0.08 (0.12)	0.531	0.06 (0.08)	0.476	-0.07 (0.12)	0.562	-0.05 (0.11)	0.681	0.06 (0.08)	0.471
Marital status (married)	-1.12 (0.98)	0.256	-0.23 (0.65)	0.719	-1.01 (0.96)	0.294	-0.72 (0.89)	0.423	-0.22 (0.63)	0.729
Employment status (employed)	-0.86 (1.12)	0.446	-0.83 (0.74)	0.265	-1.07 (1.10)	0.336	-1.59 (1.03)	0.122	-0.81 (0.73)	0.267
HAM-A			0.69 (0.04)	<0.001**					0.58 (0.05)	<0.001**
NRS					0.49 (0.15)	<0.001**			-0.25 (0.13)	0.050*
T-PRI							0.64 (0.09)	<0.001**	0.22 (0.09)	0.014*
R <sup>2</sup> (%)	0.3	0.333	56.5	<0.001**	3.9	0.009**	17.2	<0.001**	59.0	<0.001**
R <sup>2</sup> change (%)			56.2	<0.001**	3.6	<0.001**	16.9	<0.001**	58.7	<0.001**

SE are the standard errors of the beta estimates. The p-values were obtained from the hypothesis test on the regression coefficients. \*Moderately significant .01 < p-value ≤ .05. \*\*Strongly significant p-value ≤ .01

Abbreviations: K-OLP, keratotic oral lichen planus; HAM-A, Hamilton Rating Scale for Anxiety; HAM-D, Hamilton Rating Scale for Depression; HC, healthy controls; NRS, Numeric Rating Scale; T-PRI, Total Pain Rating Index



which exhibits symptomatic lesions and a higher level of intensity and quality of pain [6, 29]. However, the high prevalence of psychological distress and an unexpected symptomatology has been found also in the subset of patients with K-OLP [6, 7, 24, 30], a finding which continues to be an enigma considering that this subtype is considered to be asymptomatic and with a lower risk of cancerization, with the result that patients are not often followed-up in most countries [4, 5, 31].

The results of this study showed a higher prevalence of A and D in patients with K-OLP compared with HC. Indeed, A and D, respectively, were found in 52.7% (158) and 49.3% (148) of K-OLP patients, with the majority showing mild A (122; 40.7%) and mild D (118; 39.3%). The prevalence of A in K-OLP found in this study is in line with the data of a recent systematic review and meta-analysis of De Porras-Carrique T et al. [1], which has included fifty-one studies (with a total of 6815 patients). However, no data have been reported about differences between the subtypes of OLP, while, instead, the prevalence of D is higher compared with this study (31.19%). This high prevalence of A and D in K-OLP patients is surprising considering that patients with a history or occurrence of psychiatric illness were excluded from the study. Consequently, the majority of the K-OLP patients were unaware that they were suffering from A and D and had never been evaluated by a psychiatrist. This finding may suggest that people continue to be reticent to reveal or recognize that they have any psychiatric disease, particularly in certain countries such as Italy.

Burning sensation was reported by 58.3% (149) of K-OLP patients and in 15.3% (46) of these cases, this was diffused to the whole oral mucosa, reported also in sites without any lesions [6]. Despite the fact that in the dependence analysis, the intensity and quality of pain was found to be correlated with A and D ( $p$ -value  $< 0.001^{**}$ ), from the analysis of multiple linear regression, NRS and T-PRI could explain only 6.2% and 20% and 3.9% and 17.2% of the variance of A and D, respectively. In addition, it is interesting to highlight that A and D were reported in K-OLP without pain, as well as severe pain being reported also in K-OLP without A and D. Instead, A and D were strictly interconnected in patients with K-OLP as shown both by the dependence and multiple regression analyses. Indeed, D could explain 55.5% of the variance of A and A contributed to 56.2% of the variance of D. In contrast, the other variables considered together could increase the R<sup>2</sup> value by only 4.3% and 2.5% for A and D, respectively.

Therefore, from this analysis, it is possible to suppose that the symptomatology was not consistently interconnected with A and D, as shown in a previous study where the worsening of symptoms was directly associated with an increase in psychological distress. [1] Instead, it is potentially related to peripheral neuropathy, as suggested

in our previous research [6] in which the subjective perception of pain was predominantly related to the extension of the disease, independently of the clinical form of OLP. Moreover, in line with previous studies [26, 32], the A and D levels may not be significantly correlated with the severity of OLP, considering that all the patients were affected by keratotic lesions.

In the current study, the disease onset was at about 4.5 years. Therefore, it is not possible to exclude the possibility that the fear of cancerization of the disease has had an impact on susceptible patients in terms of the development of psychological distress over time. Indeed, in line with previous studies [31, 33], in this sample the prevalence of A and D was higher in women, generally considered more vulnerable to stress and more prone to develop psychiatric diseases, especially during perimenopausal endocrine changes. In addition, as suggested by the study of Mehdipor et al. [34], patients suffering from OLP have a greater tendency to experience anger, repressed and not expressed, compared to healthy subjects. Therefore, it may be possible to speculate that the continuous failure to express individual emotions, over time, may predispose subjects to a more serious psychological impairment [35].

The similarity in the biological pathways between A, D, and OLP may be explained by the involvement of the serotonergic system, which could be implicated also in the pathogenesis of OLP, as described by Kurmus et al. [13] Another possible explanation may involve the bidirectional connection between the immune system and central nervous system, in which mood disorders may influence the clinical expression of OLP by working on the functions of the immune system, which in turn may cause or aggravate neuropsychiatric diseases through the production of proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF- $\alpha$ ), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10) and interleukin 17 (IL-17) [36–39].

Interestingly, recent researches have suggested the potential role of vitamin D in reducing the expression of some pro-inflammatory cytokines [40]. Specifically, vitamin D deficiency has been correlated to higher serum levels of IL-17 and IL-6 in OLP patients, especially in the symptomatic subset [41]. In addition, the local inflammatory response in the oral mucosa towards an unknown antigen may be responsible for the peripheral neuropathy, independently of the clinical form of OLP, causing in time pain and additional symptoms [42].

Moreover, recent studies have suggested a possible role of the imbalance of the oral microbiota and host response in the development of neurodegenerative and immune diseases [43, 44]. Therefore, the oral dysbiosis may be implicated in the onset of disease and in the pathogenesis of mood disorders by acting on the brain-gut axis [45].

Indeed, although the dysbiosis in the oral microbiota is more remarkable in non-keratotic OLP, it is found also in K-OLP patients and not only may be associated with a progression of this subtype towards an erosive form but is also in accordance with the high prevalence of A and D found in these subjects [46, 47].

The results of this study have confirmed that patients with K-OLP may suffer from A and D and a complex symptomatology that may potentially influence the clinical course and the evolution of the disease. Therefore, dentists, frequently consulted by such patients initially, must be aware of these comorbidities and should carefully and routinely evaluate emotional disorders, pain/burning, and additional symptoms in the assessment of all subtypes of OLP, at the first diagnosis and during follow-up. The evaluation of the psychological profile of the patient is complex in a dental setting and requires a learning curve on the part of clinicians since the majority of K-OLP patients are unaware that they are suffering from A or D and have never been specifically examined for mood disorders.

Further prospective studies using a structured clinical psychiatric interview should be carried out to assess the specific prevalence of A, D, and others psychiatric comorbidities in order to confirm our data and to better understand the cause-effect role between mood disorders and K-OLP.

## Limitations

The results of the present study should be interpreted in light of certain limitations. Indeed, due to the cross-sectional nature of the study, it is not possible to deduce any cause-effect relationship between mood disorders (A and D) and OLP, although their strong association is suggested.

Moreover, the recruitment of the participants was undertaken in tertiary referral Oral Medicine Units, with the result that potential confounding factors may have been introduced due to the heterogeneity of the different centers. Finally, the differential diagnosis between OLP and oral lichenoid drug reactions (OLDR), which also may appear at any time even years after the drug administration, was not feasible, as at the present there are no available diagnostic tests for OLDR [4].

## Conclusions

In this large multicentric Italian study, the prevalence of A and D in relation to K-OLP was significantly higher in comparison to the control group, suggesting a strong association between A, D, and K-OLP.

Moreover, almost 60% of K-OLP patients reported oral pain/burning and additional symptoms, also in sites without any lesions. As expected, patients suffering from higher levels of A and D, also reported higher scores of pain. Despite this positive correlation, A and D have been interestingly reported in relation

to K-OLP without pain, as well as severe pain being reported also in K-OLP without A and D, suggesting that the oral discomfort may be predominantly related to the peripheral neuropathy, independently of the clinical form of the disease.

These findings may suggest that, although the neurological pathways of pain modulation and mood disorders (A and D) are similar and to some extent overlap and despite the well-established link between OLP, A, and D, there are probably other separate pathogenetic mechanisms implicated in pain perception and in the development of mood disorders which should be further elucidated.

In conclusion, any improvement in the psychological status of K-OLP patients, through appropriate treatment, may prevent the progression of the lesions and reduce the associated symptoms, thereby contributing to promote the patient's recovery and improve the prognosis.

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1007/s00784-023-04909-3>.

**Author contributions** D.A., E.C., F.C., N.C., S.L., M.M.<sup>1</sup>, M.D.M. contributed for the conceptualization of the study, the methodology, the data collection and curation, and drafted the paper. M.A. and L.D. analyzed the data and contributed in writing the manuscript. All the other Authors were involved in the data collection and reviewed the manuscript.

**Funding** Open access funding provided by Università degli Studi di Napoli Federico II within the CRUI-CARE Agreement.

**Data Availability** The data that support the findings of this study is available from the corresponding author upon reasonable request.

## Declarations

**Competing interests** The authors declare no competing interests.

**Ethics approval and consent to participate** The study was conducted in accordance with the ethical principles of the World Medical Association Declaration of Helsinki and was approved by the Ethics Committee of Federico II University of Naples, the chief investigator center (reference number: 184/18). All the other Oral Medicine departments which participated in the study had to obtain the ethical approval of their local ethics committees. All the enrolled patients provided their written informed consent to participate in the study.

**Conflict of interest** The authors have no conflict of interest to declare.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

1. De Porras-Carrique T, González-Moles MÁ, Warnakulasuriya S, Ramos-García P (2022) Depression, anxiety, and stress in oral lichen planus: a systematic review and meta-analysis. *Clin Oral Investig* 26:1391–1408. <https://doi.org/10.1007/s00784-021-04114-0>
2. González-Moles MÁ, Warnakulasuriya S, González-Ruiz I et al (2021) Worldwide prevalence of oral lichen planus: A systematic review and meta-analysis. *Oral Dis* 27:813–828. <https://doi.org/10.1111/odi.13323>
3. DeAngelis LM, Cirillo N, McCullough MJ (2019) The immunopathogenesis of oral lichen planus-Is there a role for mucosal associated invariant T cells? *J Oral Pathol Med* 48:552–559. <https://doi.org/10.1111/jop.12898>
4. Carrozzo M, Porter S, Mercadante V, Fedele S (2019) Oral lichen planus: A disease or a spectrum of tissue reactions? Types, causes, diagnostic algorithms, prognosis, management strategies. *Periodontol* 2000 80(1):105–125. <https://doi.org/10.1111/prd.12260>
5. Arduino PG, Magliano A, Gambino A et al (2021) Risk of Malignant Transformation in 3173 Subjects with Histopathologically Confirmed Oral Lichen Planus: A 33-Year Cohort Study in Northern Italy. *Cancers (Basel)* 13:5740. <https://doi.org/10.3390/cancers13225740>
6. Adamo D, Calabria E, Coppola N et al (2021) Psychological profile and unexpected pain in oral lichen planus: A case-control multicenter SIPMO study. *Oral Dis*. <https://doi.org/10.1111/odi.13787>
7. Adamo D, Cascone M, Celentano A et al (2017) Psychological profiles in patients with symptomatic reticular forms of oral lichen planus: A prospective cohort study. *J Oral Pathol Med* 46:810–816. <https://doi.org/10.1111/jop.12577>
8. Alberdi-Navarro J, Aguirre-Urizar JM, Ginestal-Gómez E (2020) Clinical presentation of burning mouth syndrome in patients with oral lichenoid disease. *Med Oral Patol Oral Cir Bucal* 25:e805–e809. <https://doi.org/10.4317/medoral.23812>
9. Skośkiewicz-Malinowska K, Malicka B, Ziętek M, Kaczmarek U (2018) Oral health condition and occurrence of depression in the elderly. *Medicine (Baltimore)* 97:e12490. <https://doi.org/10.1097/MD.00000000000012490>
10. Wang Y-H, Li J-Q, Shi J-F et al (2020) Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies. *Mol Psychiatry* 25:1487–1499. <https://doi.org/10.1038/s41380-019-0595-x>
11. Liao H, Luo Y, Long L et al (2021) Anxiety and oral lichen planus. *Oral Dis* 27:506–514. <https://doi.org/10.1111/odi.13569>
12. Kalkur C, Sattur AP, Guttal KS (2015) Role of Depression, Anxiety and Stress in Patients with Oral Lichen Planus: A Pilot Study. *Indian J Dermatol* 60:445–449. <https://doi.org/10.4103/0019-5154.159625>
13. Kurmuş GI, Gönül M, Canpolat F et al (2019) Serotonin Expression in Lichen Planus Lesions and Its Relationship with Depression/Anxiety. *Ann Dermatol* 31:146–153. <https://doi.org/10.5021/ad.2019.31.2.146>
14. Wiriyakijja P, Porter S, Fedele S et al (2020) Health-related quality of life and its associated predictors in patients with oral lichen planus: a cross-sectional study. *Int Dent J*. <https://doi.org/10.1111/ijd.12607>
15. Hsu D-Y, Chien W-C, Chung C-H et al (2022) Risk of anxiety and depression in patients with lichen planus: A nationwide population-based study. *J Affect Disord* 300:255–262. <https://doi.org/10.1016/j.jad.2021.12.127>
16. Vilar-Villanueva M, Gándara-Vila P, Blanco-Aguilera E et al (2019) Psychological disorders and quality of life in oral lichen planus patients and a control group. *Oral Dis* 25:1645–1651. <https://doi.org/10.1111/odi.13106>
17. von Elm E, Altman DG, Egger M et al (2014) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. *Int J Surg* 12:1495–1499. <https://doi.org/10.1016/j.ijsu.2014.07.013>
18. Boonstra AM, Stewart RE, Köke AJA et al (2016) Cut-Off Points for Mild, Moderate, and Severe Pain on the Numeric Rating Scale for Pain in Patients with Chronic Musculoskeletal Pain: Variability and Influence of Sex and Catastrophizing. *Front Psychol* 7:1466. <https://doi.org/10.3389/fpsyg.2016.01466>
19. Hawker GA, Mian S, Kendzerska T, French M (2011) Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). *Arthritis Care Res (Hoboken)* 63(Suppl 11):S240–252. <https://doi.org/10.1002/acr.20543>
20. Melzack R (1987) The short-form McGill Pain Questionnaire. *Pain* 30:191–197. [https://doi.org/10.1016/0304-3959\(87\)91074-8](https://doi.org/10.1016/0304-3959(87)91074-8)
21. Hamilton M (1960) A rating scale for depression. *J Neurol Neurosurg Psychiatry* 23:56–62. <https://doi.org/10.1136/jnnp.23.1.56>
22. Hamilton M (1967) Development of a rating scale for primary depressive illness. *Br J Soc Clin Psychol* 6:278–296. <https://doi.org/10.1111/j.2044-8260.1967.tb00530.x>
23. Hamilton M (1959) The assessment of anxiety states by rating. *Br J Med Psychol* 32:50–55. <https://doi.org/10.1111/j.2044-8341.1959.tb00467.x>
24. Adamo D, Ruoppo E, Leuci S et al (2015) Sleep disturbances, anxiety and depression in patients with oral lichen planus: a case-control study. *J Eur Acad Dermatol Venereol* 29:291–297. <https://doi.org/10.1111/jdv.12525>
25. Vallejo MJ, Huerta G, Cerero R, Seoane JM (2001) Anxiety and depression as risk factors for oral lichen planus. *Dermatology* 203:303–307. <https://doi.org/10.1159/000051777>
26. Radwan-Oczko M, Zwyrtsek E, Owczarek JE, Szcześniak D (2018) Psychopathological profile and quality of life of patients with oral lichen planus. *J Appl Oral Sci* 26:e20170146. <https://doi.org/10.1590/1678-7757-2017-0146>
27. Suresh KV, Shenai P, Chatra L et al (2015) Oral mucosal diseases in anxiety and depression patients: Hospital based observational study from south India. *J Clin Exp Dent* 7:e95–99. <https://doi.org/10.4317/jced.51764>
28. Rojo-Moreno JL, Bagán JV, Rojo-Moreno J et al (1998) Psychologic factors and oral lichen planus. A psychometric evaluation of 100 cases. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 86:687–691. [https://doi.org/10.1016/s1079-2104\(98\)90205-0](https://doi.org/10.1016/s1079-2104(98)90205-0)
29. Zucoloto ML, Shibakura MEW, Pavanin JV et al (2019) Severity of oral lichen planus and oral lichenoid lesions is associated with anxiety. *Clin Oral Investig* 23:4441–4448. <https://doi.org/10.1007/s00784-019-02892-2>
30. Pippi R, Romeo U, Santoro M et al (2016) Psychological disorders and oral lichen planus: matched case-control study and literature review. *Oral Dis* 22:226–234. <https://doi.org/10.1111/odi.12423>
31. Carbone M, Arduino PG, Carrozzo M et al (2009) Course of oral lichen planus: a retrospective study of 808 northern Italian patients. *Oral Dis* 15:235–243. <https://doi.org/10.1111/j.1601-0825.2009.01516.x>
32. Escudier M, Ahmed N, Shirlaw P et al (2007) A scoring system for mucosal disease severity with special reference to oral lichen planus. *Br J Dermatol* 157:765–770. <https://doi.org/10.1111/j.1365-2133.2007.08106.x>
33. Manolache L, Seceleanu-Petrescu D, Benea V (2008) Lichen planus patients and stressful events. *J Eur Acad Dermatol Venereol* 22:437–441. <https://doi.org/10.1111/j.1468-3083.2007.02458.x>

34. Mehdipour M, Taghavi Zenouz A, Farnam A et al (2016) The Relationship between Anger Expression and Its Indices and Oral Lichen Planus. *Chonnam Med J* 52:112–116. <https://doi.org/10.4068/cmj.2016.52.2.112>
35. Chandra PS, Satyanarayana VA (2010) Gender disadvantage and common mental disorders in women. *Int Rev Psychiatry* 22:513–524. <https://doi.org/10.3109/09540261.2010.516427>
36. Capuron L, Miller AH (2011) Immune System to Brain Signaling: Neuropsychopharmacological Implications. *Pharmacol Ther* 130:226–238. <https://doi.org/10.1016/j.pharmthera.2011.01.014>
37. Solimani F, Pollmann R, Schmidt T et al (2019) Therapeutic Targeting of Th17/Tc17 Cells Leads to Clinical Improvement of Lichen Planus. *Front Immunol* 10:1808. <https://doi.org/10.3389/fimmu.2019.01808>
38. Wei S-G, Yu Y, Felder RB (2018) Blood-borne interleukin-1 $\beta$  acts on the subfornical organ to upregulate the sympathoexcitatory milieu of the hypothalamic paraventricular nucleus. *Am J Physiol Regul Integr Comp Physiol* 314:R447–R458. <https://doi.org/10.1152/ajpregu.00211.2017>
39. Machado-Carvalho L, Roca-Ferrer J, Picado C (2019) IL-4/IFN- $\gamma$  inflammatory cytokine profile induces a deficient regulation of the IL-1 $\beta$ /IL-1RI/EP2/COX-2 pathway in nasal mucosa. *Respir Med* 150:136–140. <https://doi.org/10.1016/j.rmed.2019.03.008>
40. Mahmoud SB, Anwar MK, Shaker OG, El Sharkawy DA (2021) Possible Relation between Vitamin D and Interleukin-17 in the Pathogenesis of Lichen Planus. *Dermatology* 237(6):896–901. <https://doi.org/10.1159/000510539>
41. Lama HM, Hussein F, Sadek H, Abdelghany W (2022) Serum vitamin D level in healthy individuals versus patients with symptomatic and asymptomatic oral lichen planus. *Cell Mol Biol (Noisy-le-grand)* 68(2):19–25
42. Guarneri F, Guarneri C, Marini H (2014) Oral lichen planus and neurogenic inflammation: new observations and therapeutic implications from four clinical cases. *Dermatol Ther* 27:206–210. <https://doi.org/10.1111/dth.12118>
43. Tan LY, Yeo XY, Bae H-G et al (2021) Association of Gut Microbiome Dysbiosis with Neurodegeneration: Can Gut Microbe-Modifying Diet Prevent or Alleviate the Symptoms of Neurodegenerative Diseases? *Life (Basel)* 11:698. <https://doi.org/10.3390/life11070698>
44. Peterson CT (2020) Dysfunction of the Microbiota-Gut-Brain Axis in Neurodegenerative Disease: The Promise of Therapeutic Modulation With Prebiotics, Medicinal Herbs, Probiotics, and Synbiotics. *J Evid Based Integr Med* 25:2515690X20957225. <https://doi.org/10.1177/2515690X20957225>
45. McGuinness AJ, Davis JA, Dawson SL et al (2022) A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophrenia. *Mol Psychiatry* 27:1920–1935. <https://doi.org/10.1038/s41380-022-01456-3>
46. He Y, Gong D, Shi C et al (2017) Dysbiosis of oral buccal mucosa microbiota in patients with oral lichen planus. *Oral Dis* 23:674–682. <https://doi.org/10.1111/odi.12657>
47. Yu FY, Wang QQ, Li M et al (2020) Dysbiosis of saliva microbiome in patients with oral lichen planus. *BMC Microbiol* 20:75. <https://doi.org/10.1186/s12866-020-01733-7>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Authors and Affiliations

Daniela Adamo<sup>1</sup> · Elena Calabria<sup>1</sup> · Federica Canfora<sup>1</sup> · Noemi Coppola<sup>1</sup> · Stefania Leuci<sup>1</sup> · Martina Mignogna<sup>1</sup> · Lorenzo Lo Muzio<sup>2</sup> · Francesca Spirito<sup>2</sup> · Michele Giuliani<sup>2</sup> · Lorenzo Azzi<sup>3</sup> · Marta Dani<sup>3</sup> · Giuseppe Colella<sup>4</sup> · Chiara Colella<sup>4</sup> · Lucio Montebugnoli<sup>5</sup> · Davide Bartolomeo Gissi<sup>5</sup> · Mario Gabriele<sup>6</sup> · Marco Nisi<sup>6</sup> · Andrea Sardella<sup>7</sup> · Giovanni Lodi<sup>7</sup> · Elena Maria Varoni<sup>7</sup> · Amerigo Giudice<sup>8</sup> · Alessandro Antonelli<sup>8</sup> · Alessio Gambino<sup>9</sup> · Giuliana Antonucci<sup>9</sup> · Paolo Vescovi<sup>10</sup> · Marco Meleti<sup>10</sup> · Alessandra Majorana<sup>11</sup> · Elena Bardellini<sup>11</sup> · Giuseppina Campisi<sup>12</sup> · Vera Panzarella<sup>12</sup> · Francesco Spadari<sup>13</sup> · Umberto Garagiola<sup>13</sup> · Monica Pentenero<sup>14</sup> · Samuele Sutera<sup>14</sup> · Matteo Biasotto<sup>15</sup> · Giulia Ottaviani<sup>15</sup> · Margherita Gobbo<sup>15,16</sup> · Luca Guarda Nardini<sup>16</sup> · Umberto Romeo<sup>17</sup> · Gianluca Tenore<sup>17</sup> · Rosario Serpico<sup>4</sup> · Alberta Lucchese<sup>4</sup> · Carlo Lajolo<sup>18</sup> · Gioele Gioco<sup>18</sup> · Massimo Aria<sup>19</sup> · Luca D'Aniello<sup>20</sup> · Michele Davide Mignogna<sup>1</sup> · SIPMO (Italian Society of Oral Pathology, Medicine)

<sup>1</sup> Department of Neuroscience, Reproductive Sciences and Dentistry, University of Naples Federico II, Naples, Italy

<sup>2</sup> Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy

<sup>3</sup> Unit of Oral Medicine and Pathology, ASST Dei Sette Laghi, Department of Medicine and Surgery, University of Insubria, Varese, Italy

<sup>4</sup> Multidisciplinary Department of Medical, Surgical and Dental Specialties, University of Campania Luigi Vanvitelli, Naples, Italy

<sup>5</sup> Department of Biomedical and Neuromotor Sciences, Section of Oral Sciences, University of Bologna, Bologna, Italy

<sup>6</sup> Department of Surgical Pathology, Medicine, Molecular and Critical Area, University of Pisa, Pisa, Italy

<sup>7</sup> Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy

<sup>8</sup> Department of Health Sciences, Magna Graecia University of Catanzaro, Catanzaro, Italy

<sup>9</sup> Oral Medicine Section, Department of Surgical Science, CIR Dental School, University of Turin, Turin, Italy

<sup>10</sup> Department of Medicine and Surgery, Oral Medicine and Laser Surgery Unit, University Center of Dentistry, University of Parma, Parma, Italy

<sup>11</sup> Department of Medical and Surgical Specialities, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy

<sup>12</sup> Department of Surgical, Oncological, and Oral Sciences, University of Palermo, Palermo, Italy

<sup>13</sup> Department of Biomedical, Surgical and Dental Sciences, Maxillo-Facial and Dental Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy

<sup>14</sup> Department of Oncology, Oral Medicine and Oral Oncology Unit, University of Turin, Turin, Italy

<sup>15</sup> Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy

<sup>16</sup> Unit of Oral and Maxillofacial Surgery, Ca' Foncello Hospital, Treviso, Italy

<sup>17</sup> Department of Oral Sciences and Maxillofacial Surgery, University of Rome La Sapienza, Rome, Italy

<sup>18</sup> Head and Neck Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, School of Dentistry, Università Cattolica del Sacro Cuore, Rome, Italy

<sup>19</sup> Department of Economics and Statistics, University Federico II of Naples, Naples, Italy

<sup>20</sup> Department of Social Sciences, University Federico II of Naples, Naples, Italy



## Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

[onlineservice@springernature.com](mailto:onlineservice@springernature.com)